News | July 14, 2008

Medtronic Launches First Insertable Cardiac Monitor in Japan

July 15, 2008 - Medtronic Inc. today received Japanese regulatory approval for the Reveal DX Insertable Cardiac Monitor (ICM), which was designated by the Japanese government as a high-priority medical device, and is the first insertable cardiac monitor to be introduced in Japan.

The Reveal DX ICM provides insight into unexplained fainting episodes, also known as syncope. Syncope is difficult to diagnose as episodes are often too infrequent and unpredictable for detection with conventional monitoring techniques such as ECG Holter monitors or external loop recorders. These tests are limited to 24 hours and one month, respectively; combined with the constraints placed on the patient’s daily life and the limited likelihood of an event occurring during the monitoring period, the testing may fail to determine the cause of the episodes.

Inserted just under the skin of the chest area, the Reveal DX ICM is approximately the size of a memory stick; it is capable of monitoring patients for up to three years, allowing for long-term, continuous cardiac monitoring. The company said the device automatically records and saves arrhythmias, and patients may prompt the device to record any events at any time. If the patient experiences a syncopal episode, the information collected by the device may help the physician determine if the episode is attributable to an arrhythmia.
Since no similar device has been available in Japan, the Ministry of Health, Labor and Welfare designated the Reveal DX as “high priority” for approval in Japan. The device was subject to a fast-track evaluation by the Japanese government, and received regulatory approval in July 2008.

Medtronic Japan will begin marketing the Reveal DX ICM once it has attained insurance reimbursement for the device. The Reveal DX ICM is also commercially available in the United States, Western Europe and Canada.

Causes of syncope can be heart rhythm disturbances or abnormalities in the structure of the heart. Syncope can lead to serious injury or can be a precursor to sudden cardiac death. Approximately 1.5 million people worldwide suffer from unexplained syncope. In almost 10 percent of patients, syncope has a cardiac cause (in 50 percent of cases, the cause is non-cardiac; and in 40 percent of cases the cause is unknown1).

For more information: www.medtronic.com

Related Content

ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG| January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG| October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG| November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG| October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG| September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
Overlay Init